Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
27-30 April, 2026
Not Confirmed
Not Confirmed
27-30 April, 2026
Bioprocess Internation...Bioprocess International Europe
Not Confirmed
Not Confirmed
27-30 April, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
BPI Europe
Not Confirmed
Contact SupplierBPI Europe
Industry Trade Show
Not Confirmed
27-30 April, 2026
Industry Trade Show
Not Confirmed
27-30 April, 2026
Bioprocess Internation...Bioprocess International Europe
Industry Trade Show
Not Confirmed
27-30 April, 2026
Digital content
NEWS #PharmaBuzz
12 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260112318932/en/Juvena-Therapeutics-Raises-%2433.5M-Series-B-Led-by-Bison-Ventures-to-Advance-Regenerative-Biologics-Pipeline
08 Oct 2025
// PHARMIWEB
https://www.pharmiweb.com/press-release/2025-10-08/jefferson-river-capital-launches-new-life-sciences-investment-fund-jefferson-life-sciences
12 Jun 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/eli-lilly-works-out-650m-juvena-pact-find-muscle-boosting-drugs
19 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/19/3083992/0/en/Juvena-Therapeutics-Announces-Initiation-of-First-in-Human-Clinical-Trial-of-JUV-161.html
23 Jan 2024
// BUSINESSWIRE
25 Jan 2023
// BUSINESSWIRE
Drugs in Development
Details:
JUV-161 is a protein drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of undisclosed medical condition.
Lead Product(s): JUV-161
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 09, 2026
Lead Product(s) : JUV-161
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JUV-161 is a protein drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of undisclosed medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 09, 2026
Details:
The Series B financing for JUV-161, a protein targeting IGF-2R, will support the development of treatments for muscle degeneration.
Lead Product(s): JUV-161
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: Bison Ventures | Eli Lilly | Jefferson Life Sciences | Mubadala Capital | Manta Ray
Deal Size: $33.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 12, 2026
Lead Product(s) : JUV-161
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Bison Ventures | Eli Lilly | Jefferson Life Sciences | Mubadala Capital | Manta Ray
Deal Size : $33.5 million
Deal Type : Series B Financing
Juvena Therapeutics Raises $33.5M Series B Led by Bison Ventures for Biologics Pipeline
Details : The Series B financing for JUV-161, a protein targeting IGF-2R, will support the development of treatments for muscle degeneration.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
January 12, 2026
Details:
SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. Surface has initiated a single-arm Phase 2 study evaluating SRF388 in combination with pembrolizumab in patients with NSCLC.
Lead Product(s): Undisclosed
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Undisclosed
Sponsor: Eli Lilly
Deal Size: $650.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration June 11, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : $650.0 million
Deal Type : Collaboration
Eli Lilly inks $650M Juvena pact to find muscle-boosting drugs
Details : SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. Surface has initiated a single-arm Phase 2 study evaluating SRF388 in combination with pembrolizumab in patients with NSCLC.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 11, 2025
Details:
The collaboration aims to discover, develop, and commercialize drug candidates that improve muscle health and body composition.
Lead Product(s): Undisclosed
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Undisclosed
Sponsor: Eli Lilly
Deal Size: $650.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration June 11, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : $650.0 million
Deal Type : Collaboration
Eli Lilly Works Out $650M Juvena Pact to Find Muscle-Boosting Drugs
Details : The collaboration aims to discover, develop, and commercialize drug candidates that improve muscle health and body composition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 11, 2025
Details:
JUV-161 is a muscle regenerating endocrine therapy being investigated for the treatment of Myotonic Dystrophy Type 1 (DM1) and Sarcopenia
Lead Product(s): JUV-161
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 19, 2025
Lead Product(s) : JUV-161
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Juvena Therapeutics Announces Initiation of First-in-Human Clinical Trial of JUV-161
Details : JUV-161 is a muscle regenerating endocrine therapy being investigated for the treatment of Myotonic Dystrophy Type 1 (DM1) and Sarcopenia
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 19, 2025
Details:
JUV-161 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): JUV-161
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 09, 2025
Lead Product(s) : JUV-161
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
First-In-Human Study to Evaluate Single Ascending Doses of JUV-161 in Healthy Adult Volunteers
Details : JUV-161 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 09, 2025
Details:
JUV-161, identified via Juvena’s AI platform, restores muscle fiber formation, counters muscle atrophy, and enhances strength, currently in preclinical studies for DM1.
Lead Product(s): JUV-161
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 23, 2024
Lead Product(s) : JUV-161
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Juvena Receives FDA Orphan Drug Designation for JUV-161 in Myotonic Dystrophy
Details : JUV-161, identified via Juvena’s AI platform, restores muscle fiber formation, counters muscle atrophy, and enhances strength, currently in preclinical studies for DM1.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 23, 2024
Details:
JUV-161 is the only protein-based therapeutic being developed for a rare muscle-wasting disease, myotonic dystrophy type 1 (DM1).
Lead Product(s): JUV-161
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Protein
Sponsor: Mubadala Capital
Deal Size: $41.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 08, 2022
Lead Product(s) : JUV-161
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Mubadala Capital
Deal Size : $41.0 million
Deal Type : Series A Financing
Details : JUV-161 is the only protein-based therapeutic being developed for a rare muscle-wasting disease, myotonic dystrophy type 1 (DM1).
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
November 08, 2022
Details:
The grant will fund the advancement of Juvena's lead program, fusion protein therapeutic JUV-161, for the treatment of the rare muscle-wasting disease, DM1, through initial IND-enabling studies and a pre-IND FDA meeting in the next 12-16 months.
Lead Product(s): JUV-161
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Protein
Sponsor: California Institute for Regenerative Medicine
Deal Size: $3.9 million Upfront Cash: Undisclosed
Deal Type: Funding February 02, 2022
Lead Product(s) : JUV-161
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : California Institute for Regenerative Medicine
Deal Size : $3.9 million
Deal Type : Funding
Details : The grant will fund the advancement of Juvena's lead program, fusion protein therapeutic JUV-161, for the treatment of the rare muscle-wasting disease, DM1, through initial IND-enabling studies and a pre-IND FDA meeting in the next 12-16 months.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
February 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
